Drug Trial Radar · NCT03694249
Ifetroban in Treating Patients With Malignant Solid Tumors at High Risk of Metastatic Recurrence
Last checked: Nov 19, 2026Latest source record: Jun 27, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
30
Actual
Start
Dec 12, 2018
Primary completion
Apr 2025
Study completion Apr 2026
Sponsor
- Lead sponsor
- Vanderbilt-Ingram Cancer CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Cumberland Pharmaceuticals
- First posted
- Oct 3, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This pilot trial studies the side effects of ifetroban in treating patients with malignant solid tumors that are at high risk of coming back after treatment and spreading throughout the body. Platelets are a type of blood cells that help with clotting. Cancer cells stick to platelets and ride on them to get to different parts of the body. Drugs, such as ifetroban, may help these platelets become less "sticky," and reduce the chance of cancer cells spreading to other places in the body.
Conditions
- Malignant Solid Tumor
Interventions
Ifetroban SodiumDrug
Given by mouth
PlaceboOther
Given by mouth
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse eventsTime frame: Up to 30 days after completing treatment
- Adherence to treatment (participants will be provided a pill diary to record when they take their medication. Study staff will collect the pill diary from participants at their clinic visits).Time frame: Up to 12 months
- Summarized change of FACT-G score (scale = 0 to 4)Time frame: Up to 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.